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ABSTRACT
Impaired Ca2+ signaling in prostate cancer contributes to several cancer 
hallmarks, such as enhanced proliferation and migration and a decreased ability to 
induce apoptosis. Na+ influx via transient receptor potential melastatin 4 channel 
(TRPM4) can reduce store-operated Ca2+ entry (SOCE) by decreasing the driving force 
for Ca2+. In patients with prostate cancer, gene expression of TRPM4 is elevated. 
Recently, TRPM4 was identified as a cancer driver gene in androgen-insensitive 
prostate cancer. 
We investigated TRPM4 protein expression in cancer tissue samples from 20 
patients with prostate cancer. We found elevated TRPM4 protein levels in prostatic 
intraepithelial neoplasia (PIN) and prostate cancer tissue compared to healthy tissue. 
In primary human prostate epithelial cells (hPEC) from healthy tissue and in the 
androgen-insensitive prostate cancer cell lines DU145 and PC3, TRPM4 mediated large 
Na+ currents. We demonstrated significantly increased SOCE after siRNA targeting of 
TRPM4 in hPEC and DU145 cells. In addition, knockdown of TRPM4 reduced migration 
but not proliferation of DU145 and PC3 cells. Taken together, our data identify TRPM4 
as a regulator of SOCE in hPEC and DU145 cells, demonstrate a role for TRPM4 in 
cancer cell migration and suggest that TRPM4 is a promising potential therapeutic 
target.
INTRODUCTION
In prostate cancer, decreased store-operated Ca2+ 
entry (SOCE) signals contribute to several hallmark 
functions of cancer, such as increased proliferation and 
migration and a reduction in the ability to induce apoptosis 
[1-4]. In addition, diminished Ca2+ signals impair 
degradation of the androgen receptor, a well-known target 
in prostate cancer chemotherapy [5]. Therefore, potential 
therapies that target Ca2+ homeostasis, including the SOCE 
pathway, are under active investigation [6]. The molecular 
key players of SOCE are STIM1 (stromal interaction 
molecule 1) in the membrane of intracellular Ca2+ stores 
and Orai1 Ca2+ channels in the plasma membrane. Upon 
Ca2+ release from intracellular Ca2+ stores, Ca2+ dissociates 
from a luminal EF hand motif of STIM1. Consequently, 
STIM1 proteins cluster and recruit Orai1 Ca2+ channels, 
which subsequently mediate SOCE [7, 8]. STIM/Orai-
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mediated Ca2+ signaling contributes to cell migration 
in different types of cancer, including melanoma [9, 
10], glioblastoma [11, 12], renal carcinoma [13], 
hepatocarcinoma [14], breast cancer [15, 16], cervical 
cancer [17], and prostate cancer [18].
Transient receptor potential melastatin 4 channel 
(TRPM4) is a monovalent non-selective cation channel 
that is activated upon elevation of intracellular Ca2+ [19, 
20]. TRPM4 initiates an important feedback mechanism 
for intracellular Ca2+ signals, as Na+ influx via TRPM4 
can depolarize the plasma membrane potential and thus 
reduce the driving force for Ca2+ influx [19, 21]. TRPM4 
contributes functionally to the pathophysiology of several 
cardiac diseases [22-33], migration of immune and 
vascular endothelial cells [34-36], and proliferation of 
breast cancer cells [37]. TRPM4 is expressed throughout 
various tissues, and expression levels are most pronounced 
in the colon and prostate [19, 20]. TRPM4 was 
significantly elevated in cancer samples in seven of nine 
studies that compared TRPM4 mRNA expression levels 
in normal prostate gland and prostate tumor tissue (p ≤ 
0.01; www.oncomine.org, all nine studies are summarized 
in [38]). Another study found increased levels of TRPM4 
mRNA when human prostatic intraepithelial neoplasia 
(PIN; abnormal but somewhat premalignant cells) develop 
into prostate cancer cells [39]. A recent publication by 
Schinke and colleagues demonstrated elevated levels of 
TRPM4 in androgen-insensitive prostate cancer cells and 
suggested a role for TRPM4 as a cancer driver gene [38]. 
Thus far, the role of TRPM4 in prostate cancer 
has been unclear. In the present study, we investigated 
TRPM4 protein levels in human prostate tissue scored 
with the Gleason grading system. We also functionally 
characterized TRPM4 in primary human prostate epithelial 
cells (hPEC) and in androgen-sensitive (LNCaP) and 
androgen-insensitive (DU145 and PC3) prostate cancer 
cell lines. Finally, we determined the potential of TRPM4 
to limit SOCE and the functional role of TRPM4 in cell 
migration and proliferation of prostate cancer cells.
RESULTS
Elevated TRPM4 expression in PIN and prostate 
cancer cells
Prostate tissue samples contain different cell types, 
including fibroblasts and basal, luminal, and secretory 
epithelial cells, as well as neuroendocrine cells. Due to 
this heterogeneous nature, a comparison of the mRNA 
levels of a gene in cancer versus normal tissue samples is 
not entirely useful. We thus evaluated TRPM4 antibody 
staining in paraffin-embedded human prostate cancer 
tissues from 20 patients (Figure 1, Supplementary Table 
1). Figure 1 shows examples of immunohistochemical 
stainings with TRPM4-specific antibody of prostate 
cancer tissue samples that were rated with different 
Gleason scores. We found expression of TRPM4 in 
hPEC and weak or negligible expression in stromal cells 
(Figure 1). Areas identified as non-malignant (e.g. Figure 
1 panel 1, upper left and panel 2, bottom right) or benign 
prostatic hyperplasia (BPH) showed no or faint TRPM4 
immunoreactivity. In areas of PIN or increased Gleason 
growth patterns, medium or strong signal intensity of 
TRPM4 was detected (Figure 1). The specificity of the 
TRPM4 antibody was verified in consecutive tissue slices 
(α-TRPM4 and control) and with Western blot analysis 
upon an siRNA based knockdown of TRPM4 in LNCaP 
and DU145 cells (SFigure 1A and 1B). Supplementary 
Table 1 summarizes the clinical characteristics (i.e., 
classification by Gleason score and tumor nodes metastasis 
[TNM] stage) of 20 patients with prostate cancer. For 
these patients, TRPM4 signal intensities were evaluated 
in areas of tumor, PIN, and BPH. We did not observe 
any correlation between TRPM4 staining and the clinical 
or pathological stages of prostate cancer. In all tissue 
samples, we detected strong TRPM4 staining in malignant 
and PIN areas and weak or absent staining in areas with 
BPH. 
Figure 1: Immunohistochemical detection of TRPM4 in prostate cancer tissue. Representative images (original magnification, 
100×) of TRPM4-immunostained tissue sections from prostate carcinomas are shown. Red staining indicates TRPM4-positive areas. Scale 
bars represent 100 µm.
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In hPEC, TRPM4 generates large Na+ currents 
and limits SOCE
TRPM4 plays a role in several physiological 
functions such as membrane depolarization, cell death, 
migration and proliferation [26, 40]. To functionally 
determine Na+ currents via TRPM4 in hPEC, we performed 
whole-cell patch clamp analysis and evoked TRPM4 
currents with 0.1-15 µM free Ca2+ in the patch pipette. 
Intracellular Ca2+ activated TRPM4 currents in hPEC in 
a dose-dependent manner (Figure 2A; current-voltage 
curves [IV] are shown in Figure 2B). For further analysis, 
we corrected for current not specific to TRPM4, which can 
also be activated by intracellular Ca2+ e.g. Ca2+ activated 
Cl- channels [41]. To do so, after current development 
(400 s), Na+ in the external bath solution was replaced by 
NMDG, a nonpermeable cation. This abolishes all Na+ 
inward current, and the net Na+ current density (ΔCD) can 
be analyzed by subtracting NMDG currents (at 406 s) from 
currents in Na+ (at 396 s). An example of calculating ΔCD 
during analysis of a typical cell is shown in Figure 2C, 
and the corresponding IV are shown in Figure 2D. 10 µM 
Ca2+ evoked maximal ΔCD and we calculated an EC50 for 
Ca2+-dependent TRPM4 activation of 1.7 ± 0.2 µM, which 
is consistent with published EC50 values of 0.4-9.8 μM 
[19, 42-44] (Figure 2E). In an siRNA-based knockdown, 
we found a significant reduction in TRPM4 currents 72 
h after transfection (Figure 2F). Relative gene expression 
levels of TRPM4 normalized to TATA box binding protein 
(TBP) were reduced 72 h after knockdown, as shown by 
RT-PCR (Supplementary Figure 1C). Taken together, these 
experiments demonstrate that increasing intracellular 
Ca2+ concentrations generate large TRPM4-mediated Na+ 
currents (up to approximately 70 pA/pF) in hPEC.
In a fluorescence-based Fura-2 Ca2+ assay, we tested 
the potential of TRPM4 to reduce SOCE in hPEC (Figure 
3A), as a large Na+ influx can lower the driving force for 
Ca2+. Upon addition of thapsigargin (Tg), an inhibitor 
of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
(SERCA), intracellular Ca2+ stores were depleted. The 
Ca2+ release from intracellular Ca2+ stores was detected as 
a small increase in intracellular Ca2+ (400-600 s). Upon 
readdition of extracellular Ca2+ (time > 1000 s), SOCE 
was recorded as described previously [45]. After TRPM4 
knockdown, we detected elevated SOCE in hPEC (Figure 
3A). The significant increase in rate, peak, and plateau 
of SOCE after knockdown demonstrates a clear role for 
TRPM4 in limiting SOCE signals in hPEC (Figure 3B). 
TRPM4 generates large Na+ currents in prostate 
cancer cells and limits SOCE in DU145
We compared TRPM4 activity in hPEC, as well as 
in the prostate cancer cell lines LNCaP, DU145 and PC3. 
TRPM4 currents were activated with 10 µM intracellular 
Ca2+, and in case of the PC3 cells 25 µM Ca2+ were used in 
addition (Figure 4A and 4B, IV are shown in Figure 4C). 
TRPM4-nonspecific currents were subtracted as described 
Figure 2: TRPM4 currents in hPEC. A. Time course of averaged TRPM4 current densities (CD) evoked by adjusted intracellular 
Ca2+ concentrations as indicated (100 nM Ca2+, n = 7; 3 µM Ca2+, n = 12; and 15 µM Ca2+, n = 11). B. Average IV for cells in A. at time = 
396 s. C. TRPM4 current over time in a typical cell when NMDG was applied as indicated. D. IV for the typical cell in C. at indicated time 
points. E. Dose-response curve for TRPM4 currents induced with various Ca2+ concentrations: 10 nM Ca2+, n = 8; 500 nM Ca2+, n = 6; 1 
µM Ca2+, n = 8; 10 µM Ca2+, n = 10; and 300 µM Ca2+, n = 7. Same cells as in A. for 100 nM, 3 µM, and 15 µM Ca2+. EC50 for Ca2+ was 1.7 
µM. F. ΔCurrent density (ΔCD) of TRPM4 current 24 h, 48 h, and 72 h after siRNA-based knockdown of TRPM4 (light grey bars: 24 h, n 
= 7; 48 h, n = 9; and 72 h, n = 11) and control RNA treatment (dark grey bars: 24 h, n = 5; 48 h, n = 5; and 72 h, n = 9). 
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above. Whereas in hPEC TRPM4 exhibited currents of 70 
± 13 pA/pF, in the prostate cancer cell lines, the TRPM4 
current size was 35 ± 12 pA/pF in LNCaP, 59 ± 17 pA/
pF in DU145, 9 ± 5 pA/pF in PC3 cells for 10 µM Ca2+ 
and 56 ± 11 pA/pF in PC3 cells for 25 µM Ca2+ (Figure 
4B). The corresponding IV are shown in Supplementary 
Figure 2A-2C. While in hPEC 10 µM intracellular Ca2+ 
evoked maximal current (Figure 2E), current development 
in cancer cells is slower and can be further enlarged with 
increasing intracellular Ca2+ concentrations as has been 
demonstrated here for PC3 cells (Figure 4A and 4B).
siRNA-based knockdown of TRPM4 significantly 
reduced the current size in LNCaP (Figure 4D; IV are 
shown in Supplementary Figure 3A) and DU145 (Figure 
4E; IV are shown in Supplementary Figure 3B), and 
reduced current size in PC3 (Figure 4F; IV are shown in 
Supplementary Figure 3C) demonstrating the TRPM4-
specificity of the detected currents in prostate cancer 
cells. Knockdown efficiency after 72 h was determined 
by RT-PCR, as shown in Supplementary Figure 4A-4C. 
We also controlled for off-target effects of the TRPM4 
specific siRNA within the SOCE pathway and found that 
expression levels of Orai1, Orai2, Orai3, STIM1 and 
STIM2 remain largely unchanged (Supplementary Figure 
4D and 4E).
As in human prostate cancer tissue TRPM4 was 
up-regulated (Figure 1); in native cancer cells, TRPM4 
currents might well exceed TRPM4 currents in hPEC, 
Figure 3: TRPM4 limits SOCE in hPEC. A. Thapsigargin-induced SOCE in hPEC transfected with control RNA (black, n = 338; 
two donors) or TRPM4 siRNA (grey, n = 265; two donors) 72 h after transfection measured in a Fura-2-based Ca2+ readdition protocol. B. 
Analysis of the rate, peak, and plateau of Ca2+ entry of cells shown in A.
Figure 4: TRPM4 currents in hPEC, LNCaP, DU145 and PC3. A. Time course of averaged TRPM4 current densities (CD) in 
hPEC, LNCaP, DU145 and PC3 evoked by 10 µM Ca2+ if not indicated otherwise, hPEC (n = 10, same cells as in 2E., LNCaP (n = 10), 
DU145 (n =7) and PC3 (n = 6 for 10 µM Ca2+ and n = 5 for 25 µM Ca2+). B. ∆CD from cells in A.. C. IV at t = 396 s for cells in A.. D. ∆CD 
evoked with 10 µM Ca2+ in the patch pipette in LNCaP cells transfected with control RNA (dark grey bar, n = 5) or siRNA to down-regulate 
TRPM4 (light grey bar, n = 6). E. ∆CD evoked with 10 µM Ca2+ in the patch pipette in DU145 cells transfected with control RNA (dark 
grey bar, n = 5) or siRNA to down-regulate TRPM4 (light grey bar, n = 7). F. ∆CD evoked with 10 µM Ca2+ in the patch pipette in PC3 cells 
transfected with control RNA (dark grey bar, n = 5) or siRNA to down-regulate TRPM4 (light grey bar, n = 5).
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even though under the conditions used here TRPM4 
currents in cancer cell lines were lower than in hPEC.
To further delineate the role of TRPM4 in prostate 
cancer, we investigated the potential of TRPM4 to limit 
Ca2+ signals in the prostate cancer cell lines DU145 and 
PC3. We performed the same Fura-2 based Ca2+ assay 
as in Figure 3A for DU145 (Figure 5A). In DU145 cells, 
knockdown of TRPM4 significantly increased the rate, 
peak, and plateau of SOCE (Figure 5A and 5B). When 
the membrane potential is clamped close to 0 mV (high 
K+ Ringer), knockdown of TRPM4 only slightly increase 
the peak of SOCE while the Ca2+ entry rate and plateau 
of SOCE remained unchanged (SFigure 5A). Under these 
conditions the relative increase in SOCE upon knockdown 
of TRPM4 is significantly reduced for the Ca2+ entry rate 
and plateau of SOCE (SFigure 5B) compared to standard 
conditions. We conclude that upon activation of TRPM4 
the concomitant Na+ influx leads to a depolarization of 
the membrane potential. Thus the driving force for Ca2+ 
entry is reduced and SOCE is limited. In PC3 cells we did 
not detect increased SOCE upon knockdown of TRPM4 
(SFigure 6).
Both, DU145 and PC3 cells exhibit large TRPM4 
currents and in addition TRPM4 significantly reduced 
SOCE in DU145 cells. Thus, we investigate the function 
of TRPM4 in androgen-insensitive prostate cancer cells 
DU145 and PC3. 
Figure 5: TRPM4 limits SOCE in in DU145. A. Thapsigargin-induced SOCE in DU145 transfected with control RNA (black, n = 
338) or TRPM4 siRNA (grey, n = 215) measured during a Ca2+-readdition protocol 72 h after transfection. B. Analysis of the rate, peak, and 
plateau of Ca2+ entry of cells shown in A..
Figure 6: Down-regulation of TRPM4 leads to reduced migration potential of DU145 cells. A.-C. Migrated cells when 
DU145 cells were either not transfected A. or transfected with control RNA B. or siRNA against TRPM4 C.. D. Analysis of migration of 
cells in (A.-C.). E. Proliferation of cells in (A.-C.).
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TRPM4 in migration and proliferation
We tested the migration of DU145 and PC3 cells 
when cells were either non-transfected or transfected with 
control RNA or siRNA targeting TRPM4 (Figure 6A-
6D and 7A-7D). Although transfection had a clear effect 
on the migration potential of these cells, knockdown 
of TRPM4 resulted in a strong decrease in migration 
compared to control transfected cells (Figure 6D and 
Figure 7D). Figure 6E and 7E show that transfection 
affected the proliferation of the DU145 and PC3 cells, 
but there was no difference between TRPM4 siRNA- 
or control RNA-transfected cells. To summarize, the 
decreased migration of transfected DU145 and PC3 cells 
upon control transfection can be explained by decreased 
proliferation, but knockdown of TRPM4 also specifically 
reduces the migration of DU145 and PC3 cells.
DISCUSSION
Cell migration depends on intracellular Ca2+ and 
lately the spatial and temporal organisation of STIM/
Orai dependent Ca2+ gradients has been revealed [46-
48]. In addition to SOCE channels, several TRP channels 
contribute to the migration of cancer cells, including TRP 
channels TRPC1, TRPM7, TRPM8, TRPV1, TRPV2, and 
TRPV6 [3]. TRPM4 is known to generate an important 
feedback mechanism for SOCE and to contribute to 
the migration of dendritic cells, mast cells and vascular 
endothelial cells [19, 21, 34-36, 49].
We demonstrated that TRPM4 protein levels in 
areas of PIN and human prostate cancer tissues rated 
with different Gleason scores were elevated compared 
to TRPM4 expression in healthy tissue or areas of 
BPH. These findings are in line with several studies that 
demonstrate increased levels of TRPM4 mRNA in prostate 
cancer samples compared to healthy tissues (summarized 
in [38]). 
TRPM4 conducted large Na+ currents in both, hPEC 
and in prostate cancer cell lines. We here investigated the 
role of TRPM4 in prostate cancer cells that - in contrast 
to hPEC - are characterized by several pathophysiological 
changes in cellular functions such as unlimited 
proliferation and enhanced migration potential. Even 
though the current in DU145 and PC3 cells may be lower 
than in native cancer cells, here, DU145 and PC3 serve 
as model cell lines to investigate the function of TRPM4 
in androgen-insensitive prostate cancer. In both prostate 
cancer cell lines knockdown of TPRM4 reduced migration 
while proliferation remained unaffected. 
In DU145 cells activation of TRPM4 depolarizes 
the membrane potential, reduces the driving force for Ca2+ 
and is thus an important negative feedback regulator of 
SOCE. While TRPM4 regulates SOCE in DU145 cells 
we could not detect a regulatory role for TRPM4 on Ca2+ 
Figure 7: Down-regulation of TRPM4 leads to reduced migration potential of PC3 cells. A.-C. Migrated cells when PC3 
cells were either not transfected A. or transfected with control RNA B. or siRNA against TRPM4C.. D. Analysis of migration of cells in 
(A.-C.). E. Proliferation of cells in (A.-C.).
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signaling in PC3 cells, probably due to the slower current 
activation and/or limitations of our Ca2+ imaging protocol. 
A very recent study describes TRPM4 as a component of 
the adhesome required for migration. TRPM4 contributes 
to cell migration not only by regulating intracellular 
Ca2+ signaling but also by direct interaction with several 
proteins involved in actin cytoskeleton dynamics [50]. 
Thus the regulatory mechanism of TRPM4 on migration 
of prostate cancer cells may differ in DU145 and PC3 cells 
and include Ca2+ independent mechanisms. 
While Armisen et al. clearly demonstrate a role for 
TRPM4 in the proliferation of breast cancer cells [37], we 
cannot detect a TRPM4-specific effect on proliferation 
of prostate cancer cells. One explanation may be that 
the transfection of prostate cancer cells itself has a clear 
impact on their proliferation which may cover any specific 
contribution of TRPM4. Another explanation could be that 
TRPM4 regulates proliferation in breast cancer cells while 
in prostate cancer TRPM4 does not impair proliferation.
Disordered Ca2+ signals in cancer have been 
investigated for decades, and consequently several 
therapeutic strategies have been developed to target 
Ca2+-transporting enzymes [4, 6]. Currently, the prostate-
targeted thapsigargin derivative mipsagargin is being 
tested in a phase II clinical trial [51]. Advanced strategies 
based on calmodulin antagonists that further sensitize 
prostate cancer cells to thapsigargin therapies have 
delivered promising results [52]. 
Down-regulation of TRPM4 strongly decreased cell 
migration of DU145 and PC3 cells, suggesting a role for 
TRPM4 in prostate cancer invasion—the initial step for 
tumor metastasis. We suggest that up-regulation of the 
TRPM4 cancer driver gene [38] functionally contributes to 
the development of PIN and prostate cancer by elevating 
the migration potential of androgen-insensitive prostate 
cancer cells. TRPM4 contributes to the migration of 
prostate cancer cells and is thus an interesting potential 
pharmacological target. The ubiquitous expression pattern 
of TRPM4 implies a versatile role for TRPM4 in cancer 
cell migration.
MATERIALS AND METHODS
Immunohistochemistry
This study was approved by the local ethical 
review board and was performed in accordance with 
the Declaration of Helsinki. After we received written 
informed consent, prostate cancer tissues from 20 patients 
were obtained after radical prostatectomy from thus 
far untreated prostate cancer patients. Gleason score, 
pathologic stage, histologic diagnosis, and tumor node 
metastasis classification (TNM) were done in accordance 
with the guidelines of the Union for International 
Cancer Control (2002). Tissue samples were cut into 
3 µm thick sections, transferred onto Superfrost Ultra 
Plus Microscope Slides (Menzel-Gläser, Braunschweig, 
Germany), and dried in an incubator at 37°C overnight. 
After deparaffinization, heat-induced epitope retrieval was 
performed by treatment in 10 mmol/L citrate buffer (pH 
6.0) and nonspecific protein binding sites were blocked by 
incubation in blocking solution (80 mL of 0.1M Tris-HCl 
pH 7.2, 3 g of bovine serum albumin [BSA; Sigma Aldrich, 
Germany], and 20 mL of fetal bovine serum [FBS; Sigma 
Aldrich Chemie GmbH]) for 30 min at room temperature. 
Subsequently, primary antibody incubation was performed 
with a 1:100 solution (diluted in phosphate-buffered 
saline/0.3% BSA) of a specific TRPM4 monoclonal 
mouse antibody ([53] Clone 10H5, TA500381; Origene, 
Rockville, MD, USA) overnight at 4°C. Each staining 
series included negative controls without α-TRPM4 
incubation. Visualization was performed with the DAKO 
Real Detection System (DAKO, Glostrup, Denmark) in 
accordance with the manufacturer’s instructions, and 
slides were counterstained with hematoxylin. TRPM4 
staining intensity was classified as no staining (0), weak 
(+), intermediate (++), or strong (+++).
Cell culture and prostate tissue collection
Lymph node carcinoma of the prostate (LNCaP) 
cells, DU145 and PC3 were purchased from the American 
Type Cell Culture Collection (ATCC, Rockville, MD, 
USA) and cultured in RPMI Medium 1640 (Life 
Technologies) supplemented with 10% FCS and 1% 
penicillin/streptomycin (Life Technologies). Prostate 
tissue was obtained from prostectomy specimens (ethics 
approval 168/05, Ärztekammer des Saarlandes), and hPEC 
were isolated, with slight modifications, in accordance 
with [54], as described in [45]. 
Western blot analysis
For Western blot analysis, cells were lysed and 200 
µg of total protein was separated by 10% SDS-PAGE. 
Immunoblots were probed with anti-TRPM4 antibody 
(1:250; Origene). The manusfacturer’s control was used to 
test for positive TRPM4 staining. Antibodies and proteins 
were detected with an enhanced chemiluminescence 
detection system (ECL; Biorad).
Quantitative real-time PCR (qRT-PCR)
Total RNA from LNCaP, DU145, PC3 and hPEC 
was isolated with TRIzol Reagent (Life Technologies) 
and from prostate tissue with the RNeasy Mini kit 
(Qiagen). For reverse transcription, 0.8 µg of isolated 
total RNA was used. Complementary DNA (cDNA; 0.5 
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µl) and 300 nM primer were used with a QuantiTect 
SYBRgreen kit (Qiagen). PCR conditions were as follows: 
15 min at 95°C; 45 cycles of 30 s at 95°C, 45 s at 58°C, 
and 30 s at 72°C; and finally a cycle (60 s at 95°C, 30 
s at 55°C, and 30 s at 95°C) to determine specificity 
by a dissociation curve using the MX3000 cycler 
(Stratagene). Expression of target genes was normalized 
to expression of the reference genes RNA polymerase II 
(RNAPol, NM_000937) and/or TATA box binding protein 
(TBP, NM_003194). Primer sequences for TRPM4 
(NM_017636) were 5′-gtatctgctctcggacaag-3′ (forward) 
and 5′-aagagctgaggaaactgcat-3′ (reverse). 
Ca2+ imaging
Ca2+ imaging experiments were performed in 
accordance with [55]. Cells were cultured overnight 
on glass cover slips and loaded with 1 μM Fura-2/
AM at 37°C for 20 min. Glass coverslips were placed 
in a perfusion chamber in a Zeiss Axio Observer.A1 
fluorescence microscope equipped with a “Plan-Neofluar” 
20×/0.4 objective (Zeiss). The excitation light, generated 
by a Polychrome V in a TILL Photonics real-time imaging 
system, alternated at 340 and 380 nm, and the exposure 
time was set to 50 ms in each channel. Light intensity at 
emission wavelength 440 nm was detected every 5 s and 
digitized by a charge-coupled device camera (Q-Imaging 
Retiga 2000RV). Bath solution contained (in mM): 155 
NaCl, 4.5 KCl, 2 MgCl2, 10 D-glucose, and 5 Hepes 
(pH 7.4 with NaOH). CaCl2 and thapsigargin in the bath 
solution was adjusted as indicated. Stock solutions of 
thapsigargin were prepared in DMSO at a concentration 
of 1 mM. In the experiment in SFigure 5 the bath solution 
contained (in mM): 155 KCl, 2 MgCl2, 10 D-glucose, and 
5 Hepes (pH 7.4 with NaOH).
Electrophysiology
Cells were patched in a tight-seal whole-cell 
configuration as described in [56, 57]. Every 2 s, voltage 
ramps of 50 ms duration from a holding potential of 0 
mV, spanning −100 mV to +100 mV, were delivered by 
a Patchmaster software-controlled EPC-10 patch-clamp 
amplifier (HEKA). Before each voltage ramp, capacitive 
currents were determined and corrected. Data were 
filtered at 1 kHz and sample rate was 3 kHz, and the liquid 
junction potential was corrected (−10 mV). For analysis, 
currents were extracted at −80 mV and 80 mV, normalized 
to the cell capacity, and plotted versus time. Bath solutions 
contained (in mM): 140 NaCl, 0.5 CaCl2, 3 MgCl2, 10 
HEPES, and 30 glucose. pH was adjusted with NaOH to 
7.2, and osmolarity was 330 mOsmol/L. In the N-methyl-
d-glucamine (NMDG) bath solution, 140 mM NaCl was 
replaced by 140 mM NMDG. Pipette solution contained 
(in mM): 140 Cs glutamate, 10 HEDTA, 10 HEPES, 8 
NaCl, MgCl2, and CaCl2. MgCl2 and CaCl2 were calculated 
(http://www.stanford.edu/ wcpatton/ webmaxcS.htm) and 
added to reach an end concentration for free Mg2+ of 3 
mM and free Ca2+ as indicated.
Data analysis and statistics
Data are given as means ± standard error of 
the mean (SEM) and were analyzed with TILLVision 
(TILL Photonics), Fitmaster 2.35 (HEKA), Igor Pro 
(Wavemetrics), and Microsoft Excel (Microsoft). Asterisks 
indicate significance and were determined by unpaired, 
two-sided Student’s t-test: *, p < 0.05; **, p < 0.01; and 
***, p < 0.001. Half maximal effective concentration 
(EC50) was determined by a fit with Hill’s equations (least-
squares method). For Ca2+ imaging, intracellular Ca2+ 
concentration was calculated from the equation [Ca2+]i = 
K(R−Rmin)/(Rmax-R), in which K, R, Rmin, and Rmax were 
determined in the corresponding in situ calibration for 
hPEC, LNCaP, and DU145 cells, in accordance with [58]. 
For qRT-PCR, relative expression was calculated with the 
∆Cq method (2−∆Cq) and Cq values were determined with 
the MX3000.
Small interfering RNA transfection (siRNA)
TRPM4 siRNAs were 5′-GCACGACGUUC 
AUAGUUGATT-3′ (sense) and 3-′GACGUGCUGCAA 
GUAUCAACU-5′ (antisense) (Qiagen). Non-silencing 
RNA were MS_control_mod [sense: 5’OmeA-OMeA-
AGGUAGUGUAAUCGCd(CUU) OMeG-OmeT-
OMeT3’; antisense: 3’OmeT-OmeTUCCAUCACA 
UUAGCGGAAdC5’]. Nucleofector II (Amaxa Lonza) 
nucleofector and the Nucleofector Transfection Kit R 
(Lonza) were used in accordance with the manufacturer’s 
instructions to transfect 0.12 nmol siRNA per transfection. 
Migration potential analysis
Migration was tested with the BD Falcon 
FluoroBloksystem (BD Biosciences, Franklin Lakes, NJ, 
USA) in 24-well inserts. A total of 2.5 × 104 DU 145 or 
PC3 cells treated with control RNA or TRPM4 siRNA 
were loaded into this system in RPMI-1640 medium 
containing 1.0% FBS. The inserts were placed in RPMI-
1640 medium with 10% FBS as an attractant. After 48 
h, the cells were fixed with methanol and stained with 
DAPI and migrating cells were analyzed on the backside 
of the membrane by fluorescence. The experiment was 
repeated three times, and the migrated cells of at least 
three individual images were automatically counted using 
NIS-Elements AR Software (Nikon).
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Real-time cell proliferation analysis
The xCELLigence SP system (Roche Diagnostics 
GmbH, Mannheim, Germany) was used for real-time 
analysis of cell proliferation. In this system, 5.0 × 
103 DU145 cells or PC3 cells, either untransfected or 
transfected with control RNA or TRPM4 siRNA, were 
seeded into a 96-well E-plate (Roche Diagnostics GmbH) 
in accordance with the manufacturer’s instructions. Cells 
pretreated with siRNA were seeded 72 h after transfection. 
Cell proliferation was monitored for 96 h, and data were 
evaluated with RTCA 2.0 software (Roche Diagnostics 
GmbH). 
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